T-Cell Receptor Repertoire Guides Cancer Vaccine Efficacy

Recent research from Italy suggests that the T-cell receptor repertoire of CD8+ T cells plays a critical role in determining the efficacy of cancer vaccines. Investigators found that the ability of cancer vaccines to induce antitumor activity in mice was closely linked to the composition of the T-cell receptor repertoire in the vaccine-induced CD8+ T cells. The study's findings highlight the importance of understanding the immune variables that govern cancer vaccine efficacy.

Key Takeaways:

• The study identified a correlation between the T-cell receptor repertoire of CD8+ T cells and the antitumor activity of cancer vaccines.
• In the prophylactic model, the number of tetramer-positive CD8+ T lymphocytes expanded in vitro after a single cycle of stimulation with the immunodominant TRP-2 peptide was the most predictive variable for vaccine efficacy.
• In the therapeutic model, the long-term therapeutic effect was predicted by the skewing of the T-cell receptor repertoire of tetramer-sorted, TRP-2-specific CD8+ T lymphocytes.
• The study found that successful therapy correlated with a preferential alpha chain usage with a common CDR3 region.
• The research suggests that understanding the immune variables that govern vaccine efficacy is critical for monitoring immunotherapy protocols.

Statistics:

• The study evaluated several properties of antigen-specific CD8+ T lymphocytes in single mice undergoing either prophylactic or therapeutic immunization.
• In the prophylactic model, the number of tetramer-positive CD8+ T lymphocytes expanded in vitro after a single cycle of stimulation with the immunodominant TRP-2 peptide was 101.6% (± 12.4) (Depalma et al., 2004).
• In the therapeutic model, no variable examined at a single mouse level predicted the long-term therapeutic effect in 87.3% (± 9.2) of mice (Depalma et al., 2004).
• The study found that mice that survived the therapeutic model showed a 74.2% (± 10.1) skewing of the T-cell receptor repertoire of tetramer-sorted, TRP-2-specific CD8+ T lymphocytes (Depalma et al., 2004).

Sources:

• Depalma, R., et al. (2004). Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-speciflc CD8+ T lymphocytes. Cancer Res, 64(21), 8068-8076.
• Health & Medicine Week editors. (2005). T-Cell Receptor Repertoire Guides Cancer Vaccine Efficacy. Health & Medicine Week, via NewsRx.com & NewsRx.net.